Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMINENT-CD: Mirikizumab in Crohn's Disease
NCT07292012Phase 4Recruiting
- Sponsor
- GETAID
- Start
- May 2026
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 4 trial of mirikizumab in Crohn's disease, sponsored by GETAID. Started May 2026; status: recruiting.
02
Drugs
mirikizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT07292012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07292012.